Allergan, Amgen submit application for possible Avastin biosimilar

BY David Salazar
THOUSAND OAKS, Calif. — Amgen and Allergan on Wednesday announced their submission of a biologics license application to the Food and Drug Administration for ABP 215, a potential biosimilar of Avastin (bevacizumab). The companies said ABP 215 is the most advanced of the four oncologic biosimilars they are developing, and they believe it’s the first submission for an Avastin biosimilar. 
“ABP 215 is one of four oncology biosimilars in our pipeline, and today's BLA submission is an important milestone as Amgen seeks to expand our oncology portfolio,” Amgen EVP research and development Dr. Sean Harper said. “ABP 215 has the potential to offer an additional high-quality therapeutic option for patients diagnosed with cancer, continuing Amgen's mission of providing patients with vital medicines.”
Allergan’s chief R&D officer David Nicholson said, “Allergan is committed to developing safe and effective therapies in certain critical disease areas.”

Leave a Reply

No comments found



What area is your company focused most on in 2019?
  • Add your answer